Lassen Therapeutics is a San Diego-based biopharmaceutical company that is dedicated to developing innovative biotherapeutics to address serious diseases. Their lead program focuses on targeting interleukin-11, a cytokine that plays a central role in fibrosis. With a team of experts and a commitment to meaningful core values, Lassen Therapeutics combines cutting-edge science, advanced technology, and extensive expertise to create novel medicines that aim to improve the lives of patients.
Utilizing industry-leading antibody technologies, Lassen Therapeutics is building a pipeline of breakthrough therapeutics. Their team has a proven track record in antibody development platforms and pipelines, and they are driven by their passion for creating life-improving medicines. With a recent oversubscribed $85 million Series B financing, Lassen Therapeutics is well-positioned to advance their Phase 2 study in thyroid eye disease and continue the development of LASN500 in Investigational New Drug (IND) enabling studies.
Generated from the website